Globally, 595 million people live with osteoarthritis (OA). This number is projected to reach 1.04 billion by 2050.*

Our mission is to treat osteoarthritis and get people moving without pain.

about

Sparta is creating the first-of-its-kind chemically engineered cartilage platform, Hyalos.

The degeneration of cartilage between the joints can cause significant personal, economic, societal burden for individuals, families, and communities. In addition, acute injuries to joint cartilage can exacerbate and become debilitating over time.

We are developing cartilage-like implants for the all of the important joints in the body.

solving a massive large problem that affects the world’s population
address cartilage degeneration
intersection of chemistry, mechanical engineering,
biology

Hyalos spotlight

The first MTP hemiarthroplasty device combining Hyalos - a cartilage-mimicking hydrogel, with a proprietary titanium fixation technology for exceptional stability and bone integration.

Unlike traditional round implants, Carthyx replicates the unique biomechanics of the great toe, providing natural motion and long-lasting joint function.

With round-shaped implants, excessive cutting of the bone can lead to bad integration and loosening of the implant. With Carthix, only cartilage is removed and the cortical bone layer is smoothed.

Available in multiple sizes, the implant is designed to restore natural motion and long-lasting relief.

Hyalos is a Multi-Indication Platform

Shoulder
Thumb
Partial knee
Ormi™
Patella
Elbow
Hip
Trochlea
Ankle
Toe

Big Toe / Karthyx

Karthyx Has No Equal

Karthyx
Durable Cartilage-Like Contact Surface
Joint Conforming Head
Osseointegrative  Stem Surface
Bone Preserving
No Opposing Surface Wear
Strong Fixation
ALTERNATIVES
Non  Durable Cartilage-Mimicking Surface
Non-Conforming Head
Non-Porous Stem
Significant Bone Removal
Opposing Surface Wear
Subsidence & Loosening

Leadership team

We are a team of operators, technologists, scientists, and engineers with long histories in the pharma, medtech, and nuclear arenas, and are driven by a common purpose; we seek to advance the standard of care for osteoarthritis and get people moving again without pain.

Dushyanth Surakanti
Dushyanth Surakanti
CEO & Co-Founder
Dimitrios Angelis
Dimitrios Angelis
President & Co-Founder
Benjamin Wiley, PhD
Benjamin Wiley, PhD
CTO & Lead Inventor
Demetrius Siachames, PE
Demetrius Siachames, PE
VP & Head of Engineering
Travis Entrop
Travis Entrop
Senior R&D Engineer
Board of directors
Ken Gall, PhD
Independent Director
Independent Director
Neil S. Roth, MD
Independent Director
Independent Director
Sean Fontenot
Independent Director
Independent Director
Dimitrios Angelis
President & Co-Founder
Executive Director
Executive Director
Dushyanth Surakanti
CEO & Co-Founder
Executive Director
Executive Director
Scientific Advisory Board
Adam Yanke, MD, PhD
Kristofer J. Jones, MD
Jon Dickens, MD, LTC
Brian Waterman, MD
Seth Sherman, MD
Strategic Advisory Board
Artem Iaryguine
Artem Iaryguine
Strategic Advisor
Nick Pachuda, DPM
Nick Pachuda, DPM
Strategic Advisor
Kristen Moffat, PhD
Kristen Moffat, PhD
Strategic Advisor
Martha Shadan
Martha Shadan
Strategic Advisor

Contact us

Thank you! Your submission has been received.
We will send you an email when we have updates to share.
Oops! Something went wrong while submitting the form.
* (GBD 2021 Osteoarthritis Collaborators (2023). Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. Rheumatology, 5(9), e508–e522. 
https://doi.org/10.1016/S2665-9913(23)00163-7)